Morningstar
•
Mar 19, 2026
Novartis AG: Novartis Earnings: Portfolio Growth Mostly Offsetting Declines From Generics Erosion
Summary
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells i
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Bristol-Myers Squibb Company
Apr 30, 2026
•
BMY
Analyst Report: Eli Lilly and Company
Apr 30, 2026
•
LLY
Analyst Report: AstraZeneca PLC
Apr 30, 2026
•
AZN
